• A+
  • A-
UNIVERSIDADE DE SÃO PAULO
Close

Serological and molecular markers of hepatitis E virus infection in HIV-infected patients in Brazil

Serological and molecular markers of hepatitis E virus infection in HIV-infected patients in Brazil
  • Serological and molecular markers of hepatitis and virus infection in HIV-infected patients in Brazil

Source

Editora Springer

Archives of Virology – Virology Division of the International Union of Microbiological Societies

Authors

A. C. Ferreira, Michele Soares Gomes-Gouvêa, G. Lisboa-Neto,  M. C. J. Mendes-Correa, C. M. Picone, N. A. Salles, A. Mendrone-Junior, F. J. Carrilho e J. R. R. Pinho

Abstract

In Brazil, the circulation of hepatitis E virus (HEV) has been demonstrated in distinct groups of individuals and some animals, but its prevalence among individuals with human immunodeficiency virus (HIV) infection is unknown. This study aimed to assess the frequency of serological and molecular HEV markers in individuals infected with HIV from São Paulo, Brazil. Serum and plasma samples of 354 HIV-infected patients collected between 2007 and 2013 were included. All samples were tested for anti-HEV IgG and IgM antibodies and HEV RNA. Anti-HEV IgG and IgM antibodies were detected in 10.7% (38/354) and 1.4% (5/354) of the samples, respectively. Both antibodies were detected simultaneously in only two samples. HEV RNA was not detected in any sample. There was no significant correlation of anti-HEV serological status (positivity to anti-HEV IgG and/or IgM) with sex, age, CD4+ T cell count, HIV viral load, antiretroviral therapy, liver enzyme levels, or coinfection with hepatitis B virus and/or hepatitis C virus. Our study provides serological evidence of past and recent HEV infections in HIV-infected patients from São Paulo, Brazil. However, the occurrence of ongoing HEV infection appears be a rare event in this population.

 

Serological and molecular markers of hepatitis E virus infection in HIV-infected patients in Brazil

 

Download link here

Não há Comentários :(
Atenção!!! Não escreva dúvidas ou perguntas. Utilize o canal específico Fale Conosco.